An Efficacy and Safety Study of Sodium Oligomannate (GV-971) for the Treatment of Alzheimer's Disease - Trial NCT05908695
Access comprehensive clinical trial information for NCT05908695 through Pure Global AI's free database. This Phase 4 trial is sponsored by Green Valley (Shanghai) Pharmaceuticals Co., Ltd. and is currently Not yet recruiting. The study focuses on Alzheimer's Disease. Target enrollment is 1312 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Green Valley (Shanghai) Pharmaceuticals Co., Ltd.
Timeline & Enrollment
Phase 4
Jul 01, 2023
Dec 01, 2029
Primary Outcome
Change from baseline in the ADAS-cog/12 score,Change from baseline in ADCS-ADL23 score
Summary
The primary purpose of this study is to confirm the clinical efficacy and mechanism of action
 of GV-971, and identify incidence of known adverse reactions in long-term use and observe new
 adverse reactions, providing more guidance for clinical use.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05908695
Non-Device Trial